Form 4: Liquidia CFO Sells 20,000 Shares Under 10b5-1 Plan

Liquidia Corp's CFO and COO, Michael Kaseta, sold 20,000 shares of common stock for $26.1837 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Kaseta, Liquidia Corp's CFO and COO, sold 20,000 shares of common stock.
• The sale occurred on August 15, 2025, at a volume-weighted average price of $26.1837 per share, with prices ranging from $25.80 to $26.50.
• The transaction was executed under a Rule 10b5-1 trading plan adopted on December 9, 2024.
• Following the sale, Kaseta directly beneficially owns 356,412 shares.
• His remaining beneficial ownership includes 46,750 unvested restricted stock units (RSUs) from a January 11, 2023 grant, 58,281 unvested RSUs from a January 11, 2024 grant, 31,250 unvested RSUs from a January 15, 2024 grant, 112,797 unvested RSUs from a January 11, 2025 grant, and 10,417 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a pre-planned insider sale, which is a routine event and does not inherently indicate positive or negative company performance. The executive retains significant ownership.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating it was not a reaction to recent negative news or an immediate change in outlook.
• The CFO and COO retains a significant beneficial ownership of 356,412 shares, including a substantial number of unvested restricted stock units, which aligns his interests with shareholders.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces direct ownership by a key executive.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 9, 2024.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. Insider sales, even pre-planned, are common in the biotechnology and pharmaceutical sectors as executives manage their equity compensation.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider stock transaction under a Rule 10b5-1 plan, which is a common practice among executives in publicly traded companies across all industries, including biotechnology. There are no specific comparable companies, projects, or results mentioned within this filing to assess against global benchmarks.

Stakeholder Impact

• Shareholders: The sale by a key executive, even if pre-planned, might be viewed with slight caution, but the retention of significant equity ownership mitigates concerns.
• Employees: No direct impact on employees is indicated.

Key Dates

Recommendation

The filing reports a routine, pre-planned insider sale by the CFO and COO. While an insider sale reduces direct ownership, the transaction was executed under a Rule 10b5-1 plan, indicating it was not based on new, non-public information. The executive retains a substantial beneficial interest in the company, including significant unvested equity, which aligns his interests with shareholders. This specific filing does not provide new information that would warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Liquidia Corp, LQDA, Insider Sale, Form 4, Michael Kaseta, CFO, COO, Stock Transaction, 10b5-1 Plan, Equity Compensation